Thelansis

GM2 Gangliosidosis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030 Description: Indication name: GM2 Gangliosidosis GM2 gangliosidosis is an autosomal recessive metabolic disorder due to β-hexosaminidase deficiency. GM2 gangliosidosis is divided into three clinical subtypes according to the age at onset. In general, the later the disease occurs, the more slowly it progresses. Type 1 (infantile type) begins in the first year of life with rapidly progressive diffuse neurological deterioration and death before 4 years of age. GM2 gangliosidosis is caused by deficiency of (beta-1,4 N-acetyl galactosaminidase) hexosaminidase activity. The two isoenzymes are called hexosaminidase A and B. Typical infantile forms of GM2 gangliosidosis are Tay–Sachs disease and Sandhoff disease. ·        The incidence of the Tay Sachs variant in the general population is estimated to be 1.75 cases per 250,000 live births, however, Sa...